DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Zoledronic Acid Administration in Acute Spinal Cord Injury

Information source: James J. Peters Veterans Affairs Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Disuse Osteoporosis

Intervention: Zoledronic acid (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: James J. Peters Veterans Affairs Medical Center

Official(s) and/or principal investigator(s):
William A Bauman, M.D., Principal Investigator, Affiliation: James J. Peters VA Medical Center

Summary

In subjects with acute SCI: To compare the effects of parenteral zoledronic acid therapy on preservation of regional and total skeletal mass (DXA). Hypothesis: Zoledronic acid will dramatically diminish bone loss in persons with acute SCI, as evidenced by serial densitometry determinations (DXA).

Clinical Details

Official title: The Efficacy of Zoledronic Acid in the Prevention of Bone Loss in Acute Spinal Cord Injury

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Bone Mineral Density (BMD) at the Distal Femur and Proximal Tibia at Baseline and Month 12.

Secondary outcome: Bone Mineral Density (BMD) at the Total Hip at Baseline and Month 12

Detailed description: Immobilization is associated with disuse osteoporosis. Spinal cord injury (SCI) produces a syndrome of acute skeletal immobilization with immediate and irreversible unloading of the involved skeletal regions resulting in accelerated bone loss. In addition to rapid bone loss, there are also the complications of hypercalciuria, hypercalcemia, nephrolithiasis, and renal insufficiency. In some reports, as much as 50% of regional bone mass has been lost within the first year after paralysis. A depletion of regional bone of such magnitude greatly increases the risk of fractures, with associated morbidity and increased cost of care. Often, these fractures occur with minimal or non-obvious trauma and may pass undiagnosed for varying lengths of time due to the absence of pain sensation. The acute complications of fracture may include hemorrhage, deep venous thrombosis, and autonomic dysreflexia. Long-term complications include functional deformity, non-union, infection, heterotopic calcification, and significantly longer healing time. The sociology-economic consequences include a minimum of 1 to 2 weeks of hospitalization and the potential need for an increased level of attendant care. This study will address the efficacy of a bisphosphonate, zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ), in the prevention of the bone loss associated with acute SCI. Prevention of regional osteoporosis in persons with SCI would reduce the morbidity associated with fractures, a known secondary complication of immobilization. Thus, the quality of life would be improved in terms of employment responsibilities (reduction in days absent from employment and income lost) and personal activities (recreational endeavors, independence, and ease in which one performs activities of daily living). Individuals with SCI may then engage more securely in activities without fear of fracture, a tremendous psychological benefit.

Eligibility

Minimum age: 18 Years. Maximum age: 49 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Within 3 months of the date of acute SCI. 2. Motor-complete and incomplete SCI [American Spinal Injury Association Impairment Scale (AIS) of sensorimotor impairment (AIS A, B, and C)] Exclusion Criteria: 1. Extensive life-threatening injuries (in addition to SCI) 2. Femur or tibia fracture or extensive bone trauma 3. History of prior bone disease (Paget's disease, overactive parathyroid, osteoporosis) 4. Post-menopausal women 5. Known allergy to bisphosphonates 6. Severe underlying chronic illness 7. Current diagnosis of cancer or history of cancer 8. I am currently receiving corticosteroids 9. Pregnancy or lactation 10. I have been diagnosed with kidney problems 11. As determined from the prescreening blood tests by the study physician Serum creatinine > 2. 0 mg/dl 12. As determined from the prescreening blood tests by the study physician Corrected calcium < 8 mg/dl or > 11 mg/dl 13. As determined from the prescreening blood tests by the study physician Elevated liver function enzymes > 2 x upper limit of normal (ULN) 14. I am taking a bisphosphonate for heterotopic ossification (HO) (an overgrowth of bone typically diagnosed shortly after SCI in the pelvic region) 15. I have an existing dental condition or dental infection.

Locations and Contacts

Kessler Institute for Rehabilitation, West Orange, New Jersey 07052, United States
Additional Information

Related publications:

Shapiro J, Smith B, Beck T, Ballard P, Dapthary M, BrintzenhofeSzoc K, Caminis J. Treatment with zoledronic acid ameliorates negative geometric changes in the proximal femur following acute spinal cord injury. Calcif Tissue Int. 2007 May;80(5):316-22. Epub 2007 Apr 7.

Bubbear JS, Gall A, Middleton FR, Ferguson-Pell M, Swaminathan R, Keen RW. Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury. Osteoporos Int. 2011 Jan;22(1):271-9. doi: 10.1007/s00198-010-1221-6. Epub 2010 Apr 1.

Starting date: May 2006
Last updated: May 5, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017